In light of the fact that more than 90% of the patients with hyperuricemia are urate under-excretors and URAT1 is responsible for most of the uric acid reabsorption (about 90%), URAT1 inhibitors were believed to be a very efficacious and promising class of uricosuric agents for the treatment of hyperuricemia and gout [18,19]. Here, SLC22A12 is linked to hyperuricemia.